Episode 64
Biotech Hangout
00:00
Huntington's Disease: A Tough Disease to Address
There's also a 20, 25% gross to net as well. Hats off the unicure for taking on that disease but what I thought was pretty interesting gene therapy approach. Unfortunately their data that came out this week were not impressive or stock paid the price. If you go through the list of smart venture capitalists including pretty prominent ones in Boston, there's been more than a few that have been humbled by this disease. It's a very difficult disease to address and hopefully we will not stop our society from addressing Huntington's disease.
Transcript
Play full episode
